Braveheart Bio prices $382.5M IPO, tapping Hengrui-licensed BHB-1893 to challenge Bristol Myers' Camzyos and Cytokinetics' Myqorzo in cardiomyopathy.
For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately…
Braveheart Bio files for a $318.8M IPO on Nasdaq backed by a16z Bio + Health, targeting a $1.2B valuation for its heart drug…
The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.
Braveheart Bio shares surged 68% in their Nasdaq debut after a $382.5M IPO, pushing the cardiovascular biotech's market cap past…
Braveheart Bio files for a $319M Nasdaq IPO backed by a16z Bio + Health, raising questions about how crypto's biggest VC…
